Intracameral voriconazole injection in the treatment of fungal endophthalmitis developed from keratitis

ISRCTN ISRCTN84613089
DOI https://doi.org/10.1186/ISRCTN84613089
Secondary identifying numbers YCS
Submission date
13/12/2009
Registration date
06/01/2010
Last edited
06/01/2010
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Eye Diseases
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Dr Ying-Cheng Shen
Scientific

No. 160, Sec 3
Taichung Port Rd
Taichung
403
Taiwan

Study information

Study designRetrospective non-randomised non-controlled study
Primary study designInterventional
Secondary study designNon randomised controlled trial
Study setting(s)Hospital
Study typeTreatment
Participant information sheet Not available in web format, please use the contact details below to request a patient information sheet
Scientific titleIntracameral voriconazole injection in the treatment of fungal endophthalmitis developed from keratitis: a retrospective non-randomised non-controlled study
Study objectivesIntracameral voriconazole administered may effectively treat fungal endophthalmitis located at anterior chamber.
Ethics approval(s)Taichung Veterans General Hospital (VGHTC) ethics board approved in 2009
Health condition(s) or problem(s) studiedFungal endophthalmitis developed from keratitis
Intervention100 μg of voriconazole in 0.1 ml was injected into the anterior chamber using a 30-gauge needle attached to a 1.0 ml regular insulin syringe. Intracameral voriconazole injection was given once a day and the treatment discontinued while the eyes showed disappearance of the endothelial plaque and resolution of the anterior chamber fungal infiltrate. Patients diagnosed with filamentous fungal keratitis progressing to endophthalmitis who had undergone treatment with intracameral voriconazole injection and were followed up for at least 4 months.
Intervention typeDrug
Pharmaceutical study type(s)
PhaseNot Applicable
Drug / device / biological / vaccine name(s)Voriconazole
Primary outcome measureClinical observation, checked 1 month and 4 months after treatments
Secondary outcome measuresChecked 1 month and 4 months after treatments:
1. Visual acuity
2. Fungal infiltrate disappearance
Overall study start date01/01/2005
Completion date31/12/2008

Eligibility

Participant type(s)Patient
Age groupAdult
SexBoth
Target number of participants10 patients
Key inclusion criteria1. Fungal endophthalmitis from keratitis
2. Anterior chamber shows fungal web, fungal balls or endothelial plaque
3. Culture approved
4. Aged 38 - 78 years, either sex
Key exclusion criteria1. Bacterial infection
2. Culture negative
3. Fungal infection from other source
Date of first enrolment01/01/2005
Date of final enrolment31/12/2008

Locations

Countries of recruitment

  • Taiwan

Study participating centre

No. 160, Sec 3
Taichung
403
Taiwan

Sponsor information

Taichung Veterans General Hospital (VGHTC) (Taiwan)
Hospital/treatment centre

No. 160, Sec 3
Taichung Port Road
Taichung
403
Taiwan

Website http://www.vghtc.gov.tw
ROR logo "ROR" https://ror.org/00e87hq62

Funders

Funder type

Hospital/treatment centre

Taichung Veterans General Hospital (VGHTC) (Taiwan)

No information available

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing plan